Longitudinal Changes in Patient-reported Dyspnea in Patients with COPD

References

• van den Bemt L, Schermer T, van Weel C. Rational monitoring of COPD: where do current clinical guidelines stand? Eur Respir J 2007; 29(6):1078–1081.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176(6):532–555.
   PubMed Web of Science ®Google Scholar
• Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23(6):932–946.
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk DD, Balter M, Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease Û 2007 update. Can Respir J 2007; 14 Suppl B:5B–32B.
   PubMed Web of Science ®Google Scholar
• Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011; 155(3):179–191.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2011. At: www.goldcopd.com [accessed 1 March 2012].
   Google Scholar
• Mahler DA. Measurement of Dyspnea: Clinical Ratings. In: Mahler DA, O'Donnell DE, eds. Dyspnea: Mechanisms, Measurement, and Management. 2nd ed. Boca Raton, FL: Taylor & Francis; 2005: 147–165.
   Google Scholar
• Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31(2):416–469.
   PubMed Web of Science ®Google Scholar
• Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006; 27(4):822–832.
   PubMed Web of Science ®Google Scholar
• Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19(2):217–224.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22(6):912–919.
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21(1):74–81.
   PubMed Web of Science ®Google Scholar
• Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010; 65(6):473–479.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356(8):775–789.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359(15):1543–1554.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Tomlinson D, Olmstead EM, Tosteson AN, O'Connor GT. Changes in dyspnea, health status, and lung function in chronic airway disease. Am J Respir Crit Care Med 1995; 151(1):61–65.
   PubMed Web of Science ®Google Scholar
• Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995; 122(11):823–832.
   PubMed Web of Science ®Google Scholar
• Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. Longitudinal deteriorations in patient reported outcomes in patients with COPD. Respir Med 2007;101(1):146–153.
   PubMed Web of Science ®Google Scholar
• Brooks SM. Task group on surveillance for respiratory hazards in the occupational setting. ATS News. 1982; 8:12–16.
   Google Scholar
• Mahler DA, Waterman LA, Ward J, McCusker C, ZuWallack R, Baird JC. Validity and responsiveness of the self-administered computerized versions of the baseline and transition dyspnea indexes. Chest 2007; 132(4):1283–1290.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Ward J, Fierro-Carrion G, Waterman L, Lentine TF, Mejia-Alfaro R, Development of self-administered versions of the modified baseline and transition dyspnea indexes in COPD. J COPD 2004; 1:165–172.
   PubMedGoogle Scholar
• Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest 1998; 113(3):619–624.
   PubMed Web of Science ®Google Scholar
• Morris JF, Koski A, Johnson LC. Spirometric standards for healthy nonsmoking adults. Am Rev Respir Dis 1971; 103(1):57–67.
   PubMed Web of Science ®Google Scholar
• Diggle PJ, Heagerty P, Liang K, Zeger SL, eds. Analysis of Longitudinal Data. 2nd ed. Oxford University Press New York; 2002.
   Google Scholar
• Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, An Official American Thoracic Society Statement: Update on the Mechanisms, Assessment, and Management of Dyspnea. Am J Respir Crit Care Med 2012; 185(4):435–452.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166(8):1084–1091.
   PubMed Web of Science ®Google Scholar
• Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350(10):1005–1012.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A, Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182(2):155–162.
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374(9691):695–703.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124(3):834–843.
   PubMed Web of Science ®Google Scholar
• Cote CG, Celli BR. Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J 2005; 26(4):630–636.
   PubMed Web of Science ®Google Scholar
• Witek TJ, Jr, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003; 56(3):248–255.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Witek TJ, Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD 2005; 2(1):99–103.
   PubMedGoogle Scholar
• Ries AL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD 2005;2(1):105–110.
   PubMedGoogle Scholar
• Ries AL, Kaplan RM, Myers R, Prewitt LM. Maintenance after pulmonary rehabilitation in chronic lung disease: a randomized trial. Am J Respir Crit Care Med 2003; 67(6):880–888.
   Google Scholar
• California Pulmonary Rehabilitation Collaborative Group. Effects of pulmonary rehabilitation on dyspnea quality o flife and health care costs in California. J Cardiopulm Rehab 2004; 24:52–62.
   PubMedGoogle Scholar
• Stulbarg MS, Carrieri-Kohlman V, Demir-Deviren S, Nguyen HQ, Adams L, Tsang AH, Exercise training improves outcomes of a dyspnea self-management program. J Cardiopulm Rehabil 2002; 22(2):109–121.
   PubMedGoogle Scholar
• Criner GJ, Sharafkhaneh A, Player R, Conoscenti CS, Johnson P, Keyser MT, Efficacy of tiotropium inhalation powder in african-american patients with chronic obstructive pulmonary disease. COPD 2008; 5(1):35–41.
   PubMedGoogle Scholar
• de Torres JP, Pinto-Plata V, Ingenito E, Bagley P, Gray A, Berger R, Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD. Chest 2002; 121(4):1092–1098.
   PubMed Web of Science ®Google Scholar
• Fletcher C, Peto R. Natural history of chronic respiratory tract obstruction. Bull Int Union Tuberc 1978; 53(2):79–87.
   PubMedGoogle Scholar
• Casanova C, de Torres JP, Aguirre-Jaime A, Pinto-Plata V, Marin JM, Cordoba E, The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med 2011; 184(9):1015–1021.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365(13):1184–1192.
   PubMed Web of Science ®Google Scholar
• Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178(4):332–338.
   PubMed Web of Science ®Google Scholar
• Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP, Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374(9696):1171–1178.
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, Postma D, Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174(1):6–14.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Littner M, Andrews CP, Tomlinson L, Rinehart M, Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med 2008; 102(4):479–487.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354(25):2655–2666.
   PubMed Web of Science ®Google Scholar